Oxycontin manufacturer Purdue Pharma files for bankruptcy; the rise in uninsured immigrants may be associated with fear of the Trump administration's crackdown on immigrants; an investigation has found that some cannabidiol (CBD) products are being spiked in Maryland.
Oxycontin manufacturer Purdue Pharma filed for bankruptcy protection Sunday night, amid growing lawsuits alleging their role in the United States’ significant opioid epidemic, according to Reuters. Purdue announced their tentative agreement to resolve lawsuits with 24 states, 5 US territories, and lead lawyers in more than 2000 cities and counties. The board of the opioid manufacturer met Sunday evening to approve their suspected bankruptcy filing, which will allow them to restructure under terms of a proposal to settle the expansive litigation. The Sackler family, who own Purdue Pharma, proposed to cede control in the settlement, as well as pay $3 billion in cash and an additional $1.5 billion or more through the sale of another company they own called Mundipharma.New statistics suggest that the Trump administration’s crackdown on immigrants has been to blame for rising number of people without health insurance in America, according to Axios. The Census Bureau reported that the number of insured in the United States rose by 1.9 million people in 2018, which was the first jump in almost a decade. Overall, 27.5 million people (8.5%) of the population lacked health coverage in 2018. Low-income populations, most significant in Hispanics, enrolled in Medicaid were exhibited as the contributing factor behind this rise in uninsured people. Uninsured Hispanics rose by 1.6 percentage points, with 18% lacking coverage.An investigation conducted by The Associated Press revealed that some people have been substituting cheap and dangerous street drugs for the cannabis extract cannabidiol (CBD). A reporter in Towson purchased 3 CBD vape pods and tested their efficacy in labs. Results showed that 1 contained synthetic marijuana, which has sent dozens of people nationwide to emergency rooms. Unlike CBD, which has no psychoactive properties, synthetic marijuana gives people an intense high. The Towson store’s co-owner removed the brand responsible for the synthetic marijuana spiking off their shelves, but CBD industry representatives acknowledged that spiking threats remain an issue.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More